IP Library Granted Patent US 12,650,429
Granted Patent B2
US 12,650,429 · App. 17/918,926 · Granted Jun 9, 2026

Adenovirus immunoassay method and adenovirus immunoassay instrument

Inventors: Takashi Miyazawa (Gosen, JP); Miwa Kuwahara (Gosen, JP)
Assignee: DENKA COMPANY LIMITED
G01N33/56983C07K16/081G01N2333/075G01N2470/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,650,429
App. No.
17/918,926
Granted
Jun 9, 2026
Kind
B2
Abstract

An object of the present invention is to provide: a monoclonal antibody that makes it possible that adenovirus contained in a test specimen is detected and measured rapidly, simply, and with high-sensitivity; and an immunoassay for adenovirus and an immunoassay device therefor, for both of which the monoclonal antibody is used. The present invention provides: a monoclonal antibody or an antigen-binding fragment thereof, including heavy chains CDR1 to CDR3 as shown in the following (a) to (c) and a light chain CDR1 as shown in the following (d); and an immunoassay and an immunoassay device, for both of which the monoclonal antibody or the antigen-binding fragment thereof is used; (a) a heavy chain CDR1 composed of an amino acid sequence containing NY; (b) a heavy chain CDR2 composed of an amino acid sequence containing SN; (c) a heavy chain CDR3 composed of an amino acid sequence containing SYY and DY; and (d) a light chain CDR1 composed of an amino acid sequence containing NG.

Claims (18)

1 . A monoclonal antibody or an antigen-binding fragment, thereof, comprising heavy chains CDR1 to CDR3 as shown in the following (a-1) to (c-1) and light chains CDR1 to CDR3 as shown in the following (d-1) to (f-1):

(a-1) a heavy chain CDR1 consisting of an amino acid sequence of SEQ ID NO: 1;

(b-1) a heavy chain CDR2 consisting of an amino acid sequence of SEQ ID NO: 2;

(c-1) a heavy chain CDR3 consisting of an amino acid sequence of SEQ ID NO: 3;

(d-1) a light chain CDR1 consisting of an amino acid sequence of SEQ ID NO: 4;

(e-1) a light chain CDR2 consisting of an amino acid sequence of SEQ ID NO: 5; and

(f-1) a light chain CDR3 consisting of an amino acid sequence of SEQ ID NO: 6.

2 . A monoclonal antibody or an antigen-binding fragment thereof, comprising heavy chains CDR1 to CDR3 as shown in the following (a-2) to (c-2) and light chains CDR1 to CDR3 as shown in the following (d-2) to (f-2):

(a-2) a heavy chain CDR1 consisting of an amino acid sequence of SEQ ID NO: 7;

(b-2) a heavy chain CDR2 consisting of an amino acid sequence of SEQ ID NO: 8;

(c-2) a heavy chain CDR3 consisting of an amino acid sequence of SEQ ID NO: 9;

(d-2) a light chain CDR1 consisting of an amino acid sequence of SEQ ID NO: 10;

(e-2) a light chain CDR2 consisting of an amino acid sequence of SEQ ID NO: 11; and

(f-2) a light chain CDR3 consisting of an amino acid sequence containing of SEQ ID NO: 12.

3 . An immunoassay method for detecting an adenovirus, comprising performing the immunoassay of the adenovirus by using an antigen-antibody reaction between the monoclonal antibody or the antigen-binding fragment thereof according to claim 1 and adenovirus in a sample.

4 . The immunoassay method according to claim 3 , wherein the immunoassay is a sandwich method, and the monoclonal antibody or the antigen-binding fragment thereof is immobilized on a solid phase and/or is labeled for use in a sandwich immunoassay.

5 . An immunoassay device for adenovirus, comprising the monoclonal antibody or the antigen-binding fragment thereof according to claim 1 .

6 . An immunoassay method for detecting an adenovirus, comprising performing the immunoassay of the adenovirus by using an antigen-antibody reaction between the monoclonal antibody or the antigen-binding fragment thereof according to claim 2 and adenovirus in a sample.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2022
From: MIYAZAWA, TAKASHI; KUWAHARA, MIWA
To: DENKA COMPANY LIMITED
Reel/Frame 061774/0471 →
Priority Claims (1)
JP 2020-073239 · Apr 16, 2020 · national
Continuity (1)
Related Publication 20240053338A1 · Feb 15, 2024
References Cited (19)
US 4487829A · Sharp et al. · 1984 [cited by applicant]
US 11360088B2 · Inano et al. · 2022 [cited by applicant]
EP 2161285A1 · 2010 [cited by applicant]
JP 2000290298A · 2000 [cited by applicant]
JP 2000290299A · 2000 [cited by applicant]
JP 200757495A · 2007 [cited by applicant]
JP 2008196967A · 2008 [cited by applicant]
JP 201555487A · 2015 [cited by applicant]
WO WO2015015003A1 · 2015 [cited by applicant]
Extended European Search Report for European Application No. 21789366.8, dated Aug. 4, 2023. [cited by applicant]
Qiu et al., “Epitope mapping and cross-reactivity analysis of the monoclonal antibodies against hexon protein of human adenovirus type 3,” Virus Research, vol. 146, 2009 (Available online Sep. 2, 2009), pp. 58-65. [cited by applicant]
“Adenovirus Infection”, Infectious Agents Surveillance Report, vol. 38, Jul. 14, 2017, pp. 1-2 (3 pages total), with a partial translation. [cited by applicant]
Ádam et al., “Antigenic Relationships Among the Members of Adenovirus Subgenera Determined by Monoclonal Antibodies”, Acta Microbiologica Hungarica, vol. 39, No. 3-4, 1992, pp. 309-316 (10 pages total). [cited by applicant]
International Search Report for International Application No. PCT/JP2021/015541, dated Jul. 6, 2021, with an English translation. [cited by applicant]
Japanese Office Action for Japanese Application No. 2020-073239, dated Apr. 1, 2022, with an English translation. [cited by applicant]
Japanese Office Action for Japanese Application No. 2020-073239, dated Sep. 30, 2022, with an English translation. [cited by applicant]
Seto et al., “Using the Whole-Genome Sequence to Characterize and Name Human Adenoviruses”, Journal of Virology, vol. 85, No. 11, Jun. 2011, pp. 1-2. [cited by applicant]
Timoshicheva et al., “Use of Hexon as an Antigen for the Production of Monoclonal Antibodies Capable of Detecting Multiple Adenovirus Types”, Biologicals, vol. 58, 2019, pp. 44-49. [cited by applicant]
Written Opinion of the International Searching Authority for International Application No. PCT/JP2021/015541, dated Jul. 6, 2021. [cited by applicant]